Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-09-26
1993-01-26
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3726, A61K 3764, A61K 4700
Patent
active
051822580
ABSTRACT:
Compositions and methods for systemic delivery of polypeptides through the eyes are disclosed. The compositions include a systemically active polypeptide at a concentration such that the composition is substantially isotonic with tear fluid. The compositions may include a permeation-enhancing agent to aid systemic absorption of higher molecular weight polypeptides, as well as peptidase inhibitors. Therapeutically effective amounts of the polypeptide compositions can be administered to the eyes where the drug passes into the nasolacrimal duct and becomes absorbed into circulation.
REFERENCES:
patent: 4093709 (1978-06-01), Choi
patent: 4186184 (1980-01-01), Zaffaroni
patent: 4959217 (1990-09-01), Sanders et al.
Aungst et al Pharmaceutical Research, vol. 5, No. 5 (1988). pp. 305-308.
Chiou et al Journal of Ocular Pharmacology vol. 4, No. 2, 1988, pp. 165-177.
Hirai et al International Journal of Pharmaceutics vol. 9, (1981) pp. 173-184.
Monkhouse, et al., Aust. J. Pharm. (1967) 48:S70-S75.
McClure, General Pharmacology, Toxicology, and Clinical Experience, ACS Symposium Sers, The Amer. Chem. Soc. (1975) No. 14.
Lee, et al., J. Ocular Pharmacol. (1986) 2(4):345-352.
Christie, et al., J. Clin. Invest. (1931) 10:787-793.
Lee, Pharmaceutical Technology (Apr. 1987) pp. 26-38.
Lee, Pharmacy International (1985) 6:135-138.
Ueno, et al., "Ocular Pharmacology of Drug Release Devices," Controlled Drug Delivery, Stephen D. Bruck, editor, vol. II, Chapt. 4, CRC Press, Inc. (1983), pp. 90-109.
Chiou, et al., J. Ocular Pharmacol. (1988) 4(2):179-186.
Chiou, et al., Life Sciences (1988) 43(6):509-514.
Chiou, et al., Diabetes Care (1988) 11(9):750-751.
Chiou, et al., J. Ocular Pharmacol. (1989) 5(1):81-91.
Saettone, et al., J. Pharm. Pharmacol. (1984) 36:229-234.
Cashion Jr. Merrell C.
Koh Choon
Orbon Corporation
LandOfFree
Systemic delivery of polypeptides through the eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systemic delivery of polypeptides through the eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic delivery of polypeptides through the eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1412693